James Lazarovits, Archon Biosciences CEO
October 30, 2024 07:00 AM EDT
Financing
Startups
AI

A start­up backed by No­bel win­ner David Bak­er takes an AI twist on an­ti­bod­ies

Andrew Dunn

Senior Biopharma Correspondent

The newest David Bak­er biotech start­up launched Wednes­day, as Ar­chon Bio­sciences has raised a $20 mil­lion seed round to de­vel­op what it be­lieves could be …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times